참고문헌
- Sutherland EW, De Duve C. Origin and distribution of the hyperglycemic-glycogenolytic factor of the pancreas. J Biol Chem 1948;175:663-74. https://doi.org/10.1016/S0021-9258(18)57183-0
- Gromada J, Franklin I, Wollheim CB. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr Rev 2007;28:84-116. https://doi.org/10.1210/er.2006-0007
- Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 1970;49:837-48. https://doi.org/10.1172/JCI106297
- Menge BA, Gruber L, Jorgensen SM, Deacon CF, Schmidt WE, Veldhuis JD, et al. Loss of inverse relationship between pulsatile insulin and glucagon secretion in patients with type 2 diabetes. Diabetes 2011;60:2160-8. https://doi.org/10.2337/db11-0251
- Ahren B. Glucagon--Early breakthroughs and recent discoveries. Peptides 2015;67:74-81. https://doi.org/10.1016/j.peptides.2015.03.011
- Ceriello A, Genovese S, Mannucci E, Gronda E. Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol 2016;15:123. https://doi.org/10.1186/s12933-016-0440-3
- Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-9. https://doi.org/10.1016/S0140-6736(18)32590-X
- Solini A, Sebastiani G, Nigi L, Santini E, Rossi C, Dotta F. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes Metab 2017;43:512-20. https://doi.org/10.1016/j.diabet.2017.04.002
- Gormsen LC, Svart M, Thomsen HH, Sondergaard E, Vendelbo MH, Christensen N, et al. Ketone body infusion with 3-hydroxybutyrate reduces myocardial glucose uptake and increases blood flow in humans: a positron emission tomography study. J Am Heart Assoc 2017;6(3).
- Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-32. https://doi.org/10.1016/j.jacc.2010.05.034
- Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona diabetes complications study. Diabet Med 2004;21:52-8. https://doi.org/10.1046/j.1464-5491.2003.01068.x
- Nishimura E, Abrahamsen N, Hansen L, Lundgren K, Madsen O. Regulation of glucagon receptor expression. Acta Physiol Scand 1996;157:329-32. https://doi.org/10.1046/j.1365-201x.1996.35258000.x
- Manchester JH, Parmley WW, Matloff JM, Leidtke AJ, Laraia PJ, Herman MV, et al. Effects of glucagon on myocardial oxygen consumption and coronary blood flow in man and in dog. Circulation 1970;41:579-88. https://doi.org/10.1161/01.CIR.41.4.579
- Love JN, Leasure JA, Mundt DJ, Janz TG. A comparison of amrinone and glucagon therapy for cardiovascular depression associated with propranolol toxicity in a canine model. J Toxicol Clin Toxicol 1992;30:399-412. https://doi.org/10.3109/15563659209021555
- Parmley WW, Glick G, Sonnenblick EH. Cardiovascular effects of glucagon in man. N Engl J Med 1968;279:12-7. https://doi.org/10.1056/NEJM196807042790103
- Lvoff R, Wilcken DE. Glucagon in heart failure and in cardiogenic shock: Experience in 50 patients. Circulation 1972;45:534-42. https://doi.org/10.1161/01.CIR.45.3.534
- Arstila M, Iisalo E, Kallio V, Nousiainen R, Viljanen M. The effect of a long-acting glucagon preparation on endocrine and metabolic responses in acute myocardial infarction. Acta Medica Scandinavica 1974;196:423-30. https://doi.org/10.1111/j.0954-6820.1974.tb01034.x
- Nord HJ, Fontanes AL, Williams Jr JF. Treatment of congestive heart failure with glucagon. Ann Intern Med 1970;72:649-53. https://doi.org/10.7326/0003-4819-72-5-649
- McMurray JJ, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995-2008. https://doi.org/10.1056/NEJMoa1911303
- Lam CS, Chandramouli C, Ahooja V, Verma S. SGLT-2 inhibitors in heart failure: Current management, unmet needs, and therapeutic prospects. J Am Heart Assoc 2019;8:e013389.
- Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thevenet J, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21:512. https://doi.org/10.1038/nm.3828
- Ceriello A, Genovese S, Mannucci E, Gronda E. Glucagon and heart in type 2 diabetes: new perspectives. Cardiovasc Diabetol 2016;15:123. https://doi.org/10.1186/s12933-016-0440-3
- Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis. Diabetes Care 2016;39:1108-14. https://doi.org/10.2337/dc16-0330